Current status of sublingual immunotherapy in the United States

World Allergy Organization Journal

Michael S Blaiss¹  Shelby Elenburg¹ 

[1] Departments of Pediatrics and Internal Medicine, Division of Clinical Immunology and Allergy, University of Tennessee Health Science Center, 7205 Wolf River Blvd, Germantown, TN 38138, USA

关键词: Ragweed;    Grass;    Allergic rhinoconjunctivitis;    Allergic rhinitis;    Immunotherapy;    Sublingual immunotherapy;   

Others  :  1137619
DOI  :  10.1186/1939-4551-7-24

 received in 2014-04-17, accepted in 2014-08-11,  发布年份 2014

【 摘 要 】

Sublingual immunotherapy (SLIT) use in the United States to date has been limited, despite common use and demonstrated efficacy elsewhere in the world. This is largely in part due to lack of FDA-approved SLIT products, lack of established dosing and administration guidelines, and cost concerns. Several recent studies have demonstrated efficacy and safety of two sublingual grass tablets and one ragweed tablet approved by the FDA, and one sublingual ragweed liquid currently pending FDA approval. With FDA approved SLIT products, there will be numerous challenges to the allergist and patient in deciding whether to pursue SLIT or SCIT (subcutaneous immunotherapy) for allergic rhinitis. This review highlights the current state of SLIT in the United States, and expected future directions.

【 授权许可】

   
2014 Elenburg and Blaiss; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

【 参考文献 】

• [1]Sikora JM, Tankersley MS: Perception and practice of sublingual immunotherapy among practicing allergists in the United States: a follow up survey. Ann Allergy Asthma Immunol 2013, 110:194-197.
• [2]Tucker MH, Tankersley MS: Perception and practice of sublingual immunotherapy among practicing allergists. Ann Allergy Asthma Immunol 2008, 101:419-425.
• [3]Blaiss M, Dykewicz M, Skoner D, Smith N, Leatherman B, Craig T, Bielory L, Walstein N, Allen-Ramey F: Diagnosis and treatment of nasal and ocular allergies: the allergies, immunotherapy, and rhinoconjunctivitiS (AIRS) surveys. Ann Allergy Asthma Immunolin press
• [4]Bielory L, Blaiss M, Craig T, Leatherman B, Dykewicz M, Allen-Ramey F, Walstein N, Hadley J, Ortiz G, Skoner D: The allergies, immunotherapy and rhinoconjunctivitis (AIRS) provider survey: how providers differ. Ann Allergy Asthma Immunol 2013, 111(Suppl 5):A113.
• [5]Canonica GW, Bousquet J, Casale T, Lockey RF, Baena-Cagnani CE, Pawankar R, Potter PC, Bousquet PJ, Cox LS, Durham SR, Nelson HS, Passalacqua G, Ryan DP, Brozek JL, Compalati E, Dahl R, Delgado L, van Wijk RG, Gower RG, Ledford DK, Filho NR, Valovirta EJ, Yusuf OM, Zuberbier T, Akhanda W, Almarales RC, Ansotegui I, Bonifazi F, Ceuppens J, Chivato T, et al.: Sub-lingual immunotherapy: World Allergy Organization position paper 2009. Allergy 2009, 64(Suppl 91):1-59.
• [6]Maloney J, Bernstein DI, Nelson H, Creticos P, Hébert J, Noonan M, Skoner D, Zhou Y, Kaur A, Nolte H: Efficacy and safety of grass sublingual immunotherapy tablet, MK-7243: a large randomized controlled trial. Ann Allergy Asthma Immunol 2014, 112:146-153.
• [7]Nelson HS, Nolte H, Creticos P, Maloney J, Bernstein DI: Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011, 127:72-80.
• [8]Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP: Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011, 127:64-71.
• [9]Cox LS, Casale TB, Nayak AS, Bernstein DI, Creticos PS, Ambroisine L, Melac M, Zeldin RK: Clinical efficacy of 300IR 5-grass pollen sublingual tablet in a US study: The importance of allergen-specific serum IgE. J Allergy Clin Immunol 2012, 130:1327-1334.
• [10]Nolte H, Hebert J, Berman G, Gawchik S, White M, Kaur A, Liu N, Lumry W, Maloney J: Randomized controlled trial of ragweed allergy immunotherapy tablet efficacy and safety in North American adults. Ann Allergy Asthma Immunol 2013, 110:450-456.
• [11]Creticos PS, Esch RE, Couroux PC, Gentile D, D’Angelo P, Whitlow B, Alexander M, Coyne TC: Randomized, double-blind, placebo-controlled trial of standardized ragweed sublingual-liquid immunotherapy for allergic rhinoconjunctivitis. J Allergy Clin Immunol 2014, 133:751-758.
• [12]González-De-Olano D, Alvarez-Twose I: Adherence to immunotherapy in times of financial crisis. Ann Allergy Asthma Immunol 2013, 110:466-468.
• [13]Anolik R, Schwartz A, Sajjan S, Allen-Ramey F: Persistence with specific immunotherapy (SCIT & SLIT) among AR patients in a US allergy practice [abstract]. J Allergy Clin Immunol 2013, 131(Suppl 2):AB186.